Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

(2021) Yun Liang et al.   Journal of Hematology & Oncology

A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity

(2021) Huihui Zhang et al.   Science Translational Medicine

The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake

(2021) Álvaro de Mingo Pulido et al.   IMMUNITY

Phosphatidylserine binding directly regulates TIM-3 function

(2021) Courtney M. Smith et al.   BIOCHEMICAL JOURNAL

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

(2020) Shumei Kato et al.   OncoImmunology

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells

(2020) Marika Guercio et al.   HAEMATOLOGICA

IL-21-mediated expansion of Vγ9Vδ2 T cells is limited by the Tim-3 pathway

(2019) Kangni Wu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

(2019) Sara Ghorashian et al.   NATURE MEDICINE

A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function

(2019) Shiran Hoogi et al.   Journal for ImmunoTherapy of Cancer

Tim-3 hampers tumor surveillance of liver resident and conventional NK cells by disrupting PI3K signaling

(2019) Siyu Tan et al.   CANCER RESEARCH

A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21

(2018) Pavlína Ptáčková et al.   CYTOTHERAPY

A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

(2018) Yuki Kagoya et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

HMGB1 knock‐down promoting tumor cells viability and arrest pro‐apoptotic proteins via Stat3/NFκB in HepG2 cells

(2018) Salah Alduais et al.   BIOFACTORS

Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy

(2018) Kevin A. Hay   BRITISH JOURNAL OF HAEMATOLOGY

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy

(2016) C. Alvarez-Fernández et al.   Journal of Translational Medicine

206. Determining the Effect of Endogenous PD-1 Expression on the Co-Stimulatory Potential of the PD1:CD28 Chimera

(2016) Megan E. Keys et al.   MOLECULAR THERAPY

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy

(2015) Mahesh Jonnalagadda et al.   MOLECULAR THERAPY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+T cells

(2015) Chi-Keung Wan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

(2014) Yu-Hwa Huang et al.   NATURE

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells

(2013) Saskia JAM Santegoets et al.   Journal of Translational Medicine

Galectin-9 Acts as a Prognostic Factor with Antimetastatic Potential in Hepatocellular Carcinoma

(2012) Zhao-Yang Zhang et al.   Asian Pacific Journal of Cancer Prevention

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

(2012) L. C. Ndhlovu et al.   BLOOD

Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models

(2012) J. H. Shin et al.   BLOOD

Blockade of Tim-3 signaling restores the virus-specific CD8+T-cell response in patients with chronic hepatitis B

(2012) Wei Wu et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

(2011) H. Singh et al.   CANCER RESEARCH

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice

(2010) J. C. Markley et al.   BLOOD

Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

(2010) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation

(2009) M. Nakayama et al.   BLOOD

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA